Launch of the Third Phase of the Epigenetic Clock Co-Creation Project Aiming for a Society Without Fear of Aging

The Epigenetic Clock Co-Creation Project

Introduction to the Project

The Epigenetic Clock Co-Creation Project, initiated in 2024, aims to create a society that does not fear aging by bringing together companies from various industries. This program has already attracted 27 participating companies that collaborate in research, product development, and information dissemination by leveraging Rhelixa's biological age assessment technology. As the project enters its second year, there has been a noticeable increase in cases leading to clinical trials and joint releases, indicating a significant expansion in the anti-aging market driven by diverse perspectives from various sectors.

Representative's Comments

Ryu Nakaki, CEO of Rhelixa, expressed enthusiasm for the ongoing collaborations and stated, “We are excited about the opportunities to create new value together with those who share an interest in future-oriented themes, regardless of whether they have a research department or not.”

Achievements through Co-Creation

The Epigenetic Clock Project is characterized by its broad inclusion of companies interested in the anti-aging market, even those without dedicated research divisions. Through this collaboration, multiple trials and product development phases are currently underway. Significant advancements have been made in the following areas:

1. Establishing Anti-Aging Evidence through Clinical Trials

A clinical trial has been initiated that focuses on the core components of participating companies, utilizing the Epigenetic Clock measurement as the benchmark for building scientific evidence. The goal is to enhance credibility through publication and presentations at conferences, thereby fostering PR opportunities.

2. Joint Service Development Incorporating Epigenetic Clock Testing

The team is working on integrating the Epigenetic Clock test into subscription-based services, which is expected to enhance product experiences, differentiate offerings, and improve customer lifetime value (LTV).

3. Collaborative Events with Industry, Academia, and Government

Events designed to bring together key figures from industry, academia, and government are being organized. Participating companies have the opportunity to gain insights into the latest research and form collaborative partnerships.

Progress Updates

Among the companies involved, some are already making progress in research and development. For instance, Taisho Pharmaceutical and Abe Yōandon Pharma have initiated concrete collaborations, including joint press releases:

- Taisho Pharmaceutical announced their participation, highlighting their research into the relationship between taurine and aging using the Epigenetic Clock technology, aiming to push the boundaries of anti-aging research. More about Taisho
- Abe Yōandon Pharma engaged in the project’s second phase, leveraging NMN, herbal ingredients, and cutting-edge functional components to make youth visible. More about Abe Yōandon

Inquiries and Consultations

The project welcomes inquiries from companies that have an interest but might lack a research division. Interested parties are encouraged to reach out through the provided form for discussions on flexible topic settings, even if they are only exploring options at this stage. Contact Form

About Rhelixa

Rhelixa specializes in advanced genomic and epigenomic analysis. The company leverages its knowledge in biology, medicine, and pharmaceuticals to conduct foundational research, product development, and various contracted tasks. By integrating diverse genomic datasets, Rhelixa provides a thorough analysis to predict mechanisms of cellular regulation and identify high-precision markers. Moreover, they offer user-friendly environments for statistical analysis without requiring extensive foundational knowledge.